Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
A2A-04 by A2A Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
A2A-04 is under clinical development by A2A Pharmaceuticals and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
A2A-04 by A2A Pharmaceuticals for Fallopian Tube Cancer: Likelihood of Approval
A2A-04 is under clinical development by A2A Pharmaceuticals and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
A2A-04 by A2A Pharmaceuticals for Metastatic Ovarian Cancer: Likelihood of Approval
A2A-04 is under clinical development by A2A Pharmaceuticals and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...
A2A-04 by A2A Pharmaceuticals for Peritoneal Cancer: Likelihood of Approval
A2A-04 is under clinical development by A2A Pharmaceuticals and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
A2A-04 by A2A Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
A2A-04 is under clinical development by A2A Pharmaceuticals and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...